Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

/p>

Revenues:

Net product sales $108,289 $160,014 $259,526 $382,603

Other product related

revenues 4,648 7,626 8,339 19,247

Total revenues 112,937 167,640 267,865 401,850

Cost of goods sold 87,829 111,085 193,236 257,606

Gross margin 25,108 56,555 74,629 144,244

Operating expenses:

Research and development 15,955 14,277 33,113 28,316

Selling, general and

administrative 36,690 33,999 68,037 66,556

Settlements, net - - - (578)

Total operating expenses 52,645 48,276 101,150 94,294

Gain on sale of product

rights and other (500) - (2,125) (20,000)

Operating (loss) income (27,037) 8,279 (24,396) 69,950

Other (expense) income, net - (30) - (49)

Equity in loss of joint

venture (310) (80) (330) (228)

Loss on marketable

securities and other

investments, net (433) (6,040) (433) (4,643)

Interest income 2,129 3,901 5,143 6,585

Interest expense (1,667) (1,727) (3,334) (3,445)

(Loss) income from

continuing operations

before provision for

income taxes (27,318) 4,303 (23,350) 68,170

(Benefit) provision for

income taxes (7,523) 1,505 (6,081) 23,858

(Loss) income from

continuing operations (19,795) 2,798 (17,269) 44,312

Discontinued operations:

Gain from discontinued

operations - -
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... today its financial results for the year ending 31,December 2008. , , ... regulatory process for intravenous iclaprim in US, - ... of "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of ...
... better restaurant menu optionsINDIANAPOLIS, Feb. 25 This year,s ... America with the reduction of nearly a half billion ... three years. Since the market introduction in 2006, Omega-9 ... replaced more than 340 million pounds of trans fat, ...
... collaborative agreement with CureDM to continue the preclinical development of CureDM,s HIP2B ... , ... Cary, NC (PRWEB) February 25, 2009 -- Calvert ... the signing of a collaborative agreement with CureDM to continue ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3Calvert Research and CureDM Sign Collaborative Agreement 2Calvert Research and CureDM Sign Collaborative Agreement 3
(Date:9/2/2014)... accidentally touch a hot oven, you rapidly pull your ... involved in sensing and responding to such painful stimuli, ... Duke researchers have made a surprising discovery about the ... worms, and have built a structural model of the ... Communications , may help direct new strategies to treat ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
(Date:9/1/2014)... Within minutes after birth, every child in the U.S. ... host of conditions, including sickle cell disease. Thousands of ... lucky, meaning many suffer and die from the disease ... a halt to at least some of those deaths. ... Biology working in the lab of George Whitesides, the ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... connection between the body, mind and spirit has been ... years. The notion that psychosocial and societal considerations have ... crystallized as a result of the experiences of a ... writer and magazine editor of the popular Saturday Review, ...
... / b3c newswire / - Addressing significant product safety and ... has announced the commercial launch of two protease-free ... Albumin-DX (Lipid-Free) perform better in diagnostics applications than ... serum albumin (pHSA).  , , ...
... is a tragic disease that robs an individual of their memory ... 65 now suffer from the disease and one in two people ... Alzheimer,s does not only affect the elderly. Familial Alzheimer,s disease (FAD), ... The Study , Alzheimer,s is a complex ...
Cached Biology News:Laughter remains good medicine 2Laughter remains good medicine 3InVitria Announces Launch of Recombinant Albumin for Diagnostics 2Computational model examines the pathways of Alzheimer's that strikes at the young 2
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Human Serpin A3 MAb (Clone 213907)...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Biology Products: